The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and preclinical research without systematic methodology or primary human clinical trial data.
PubMed 28429672 · doi:10.2174/1566524017666170331162315
What was done
This narrative review summarizes literature regarding the molecular mechanisms of thalidomide teratogenicity and therapeutic activity. The authors analyze species-specific resistance (particularly in rodents), the molecular basis for embryonic limb malformations like phocomelia, mechanisms underlying approved clinical uses (multiple myeloma, erythema nodosum leprosum), and the degree to which teratogenic pathways overlap with therapeutic immunomodulatory, anti-inflammatory, and antiangiogenic effects.
What was found
The abstract reports no quantitative experimental data or statistical metrics. It describes historical findings (over 10,000 infants born with severe malformations following rodent-based safety assumptions) and provides qualitative evaluations of the molecular pathways distinguishing thalidomide's teratogenic and therapeutic actions to inform derivative development.
Why it matters
Clarifying the exact molecular targets responsible for thalidomide toxicity versus efficacy is necessary for rational design of drug derivatives that retain therapeutic benefit without teratogenic risk.
Limits
This is a narrative review with no primary empirical data or quantitative effect sizes reported in the abstract. Search methodology, study selection criteria, and total number of reviewed articles are not specified.
Cited by
- supports Thalidomide was originally developed as an anti-nausea drug for pregnant women, was removed from the market due to causing severe limb-reduction birth defects, and was later FDA-approved for leprosy and multiple myeloma due to its anti-angiogenic properties.